{"id":27090,"date":"2026-02-07T21:36:28","date_gmt":"2026-02-07T16:06:28","guid":{"rendered":"https:\/\/signalz.pro\/?post_type=article&p=27090"},"modified":"2026-02-07T21:36:28","modified_gmt":"2026-02-07T16:06:28","slug":"auropharma-quarterly-%e0%a4%ac%e0%a5%80%e0%a4%9f%e0%a5%8d%e0%a4%b8-%e0%a4%b8%e0%a5%87-rocket-%e0%a4%b0%e0%a4%be%e0%a4%87%e0%a4%a1-us-%e0%a4%9c%e0%a5%87%e0%a4%a8%e0%a4%b0%e0%a4%bf%e0%a4%95%e0%a5%8d","status":"publish","type":"article","link":"https:\/\/signalz.pro\/article\/auropharma-quarterly-%e0%a4%ac%e0%a5%80%e0%a4%9f%e0%a5%8d%e0%a4%b8-%e0%a4%b8%e0%a5%87-rocket-%e0%a4%b0%e0%a4%be%e0%a4%87%e0%a4%a1-us-%e0%a4%9c%e0%a5%87%e0%a4%a8%e0%a4%b0%e0%a4%bf%e0%a4%95%e0%a5%8d\/","title":{"rendered":"“Auropharma: Quarterly \u092c\u0940\u091f\u094d\u0938 \u0938\u0947 Rocket \u0930\u093e\u0907\u0921, US \u091c\u0947\u0928\u0930\u093f\u0915\u094d\u0938 \u0915\u093e \u0926\u092e\u0926\u093e\u0930 \u092a\u094d\u0930\u0926\u0930\u094d\u0936\u0928!”"},"content":{"rendered":"

Aurobindo Pharma Ltd. (AUROPHARMA) Comprehensive Equity Report:
\n<\/strong>Aurobindo Pharma, a leading generics player with US\/Europe focus, trades \u20b91,090-1,100 as of Feb 7, 2026, ahead of Q3 FY26 results (Feb 9) and earnings call Feb 10. Report covers detailed technical\/fundamental analysis, results outlook, news, and trading insights.<\/p>\n

Detailed Technical Rationale:
\n<\/strong>Daily Overview: Strong Buy (7\/9 buy signals): RSI 63.87 neutral-buy, MACD 7.54 Buy, STOCH 87.81 overbought (watch pullback), ADX 48.7 strong trend up; all 12 MAs bullish (price above EMA5-200).
\nPivot Levels (5-min): Pivot \u20b91,090.8, R1 \u20b91,103.1\u2013R2 \u20b91,123.7\u2013R3 \u20b91,136; S1 \u20b91,070.2\u2013S2 \u20b91,049.6\u2013S3 \u20b91,029.9\u2014trading near R1, high volatility expected pre-results.
\nTrend: Uptrend intact above 50-DMA ~\u20b91,050, recent consolidation from \u20b91,200 high; OBV rising confirms volume support. Enter long above \u20b91,103 (R1) targeting \u20b91,124\u2013\u20b91,136, SL \u20b91,070 (S1); post-results volatility 3-5% likely.<\/p>\n

Detailed Fundamental Analysis:
\n<\/strong>Financials (FY25E): Revenue \u20b931,724 Cr (+9.4% YoY), EBITDA \u20b96,583 Cr (12.99%), PAT \u20b93,486 Cr (+9.86%), EPS \u20b959.6; ROE ~15%, ROCE 18%, debt moderate. Growth drivers: US generics (50% revenue, ARV\/stable), Europe complex generics, oncology\/hormonal R&D (depot injections tech); 150-country footprint via subsidiaries. Valuation P\/E ~18-20x FY27E attractive vs. peers (Dr Reddy’s\/Sun Pharma); risks: US pricing pressure, FDA inspections; positives: Pipeline 200+ ANDAs, PLI benefits.<\/p>\n

Result Outlook (Feb 9, Call Feb 10):
\n<\/strong>Q3 FY26 expected: Revenue \u20b98,382 Cr (11.65% YoY), EBITDA \u20b91,792 Cr (13.94% margin), PAT \u20b91,101 Cr (22.44% YoY), EPS \u20b918.9\u2014inline-to-beat on US volumes, Europe growth despite forex headwinds. Consensus: Revenue +11-13% YoY (QoQ +2%), margins stable 13-14%; beats if USFDA approvals\/ARV demand noted. Management call (8:30 AM Feb 10, Zoom) key for FY26 guidance (revenue +10-12%, PAT +15%).<\/p>\n

News Events & Impact:
\n<\/strong>Earnings call Feb 10 (pre-reg Zoom); recent Nuvama Chemicals\/Healthcare Day (Jun 25); Investec\/Goldman meetings\u2014positive analyst interactions. No major negatives; pipeline oncology\/derma updates expected. Impact: Beat = 8-12% rally to \u20b91,200+ (R3 \u20b91,136 test); miss on margins\/US = drop to \u20b91,050 support (3-7%).<\/p>\n

Result Expectations & Stock Impact:
\n<\/strong>Expectations: Revenue inline \u20b98,300-8,400 Cr, PAT beat potential \u20b91,100 Cr+ on cost control; watch US share (50%+), guidance FY26 revenue \u20b933-35k Cr.
\nImpact: Positive surprise (PAT >\u20b91,100 Cr, margin >14%) \u2192 upside to \u20b91,150-1,200 (10%+); inline \u2192 rangebound \u20b91,080-1,110; miss (US slowdown) \u2192 \u20b91,030-1,050 (5-8% down). High volatility (ATR high), options skew call-heavy pre-results.<\/p>\n

Disclaimer & Disclosure:
\n<\/strong>Educational report only; not investment advice. Risks apply; consult SEBI-RA. Author SEBI-registered; no holdings in Aurobindo Pharma\/derivatives (Feb 7, 2026). SEBI (RA) Regs complied; public data.<\/p>\n

 <\/p>\n","protected":false},"template":"","article-category":[35],"article-tags":[388,400,130,163,112,133,169,128,116,168,127,155],"class_list":["post-27090","article","type-article","status-publish","hentry","article-category-learn","article-tags-calloptions","article-tags-technicalanalysis","article-tags-expert-analysis","article-tags-financialeducation","article-tags-financialplanning","article-tags-investment-strategies","article-tags-investmentstrategy","article-tags-sebi-registered-analysts","article-tags-signalzinvestmenttips","article-tags-stockmarkettips","article-tags-successful-investing","article-tags-wealthbuilding"],"acf":[],"_links":{"self":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article\/27090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article"}],"about":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/types\/article"}],"wp:attachment":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/media?parent=27090"}],"wp:term":[{"taxonomy":"article-category","embeddable":true,"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article-category?post=27090"},{"taxonomy":"article-tags","embeddable":true,"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article-tags?post=27090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}